This Article Full Text Full Text (PDF) CME: Take the course for this article: Therapy for Metastatic Colorectal Cancer eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Goldberg, R. M. Search for Related Content PubMed PubMed Citation Articles by Goldberg, R. M.

Special Section on Colorectal Cancer

Therapy for Metastatic Colorectal Cancer

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

Key Words. FOLFOX • FOLFIRI • Bevacizumab • N9741 • PTK 787 • Cetuximab

Correspondence: Richard M. Goldberg, M.D., CB # 7305, 3009 Old Clinic Building, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. Telephone: 919-966-5720; Fax: 919-966-6735; e-mail: goldberg{at}med.unc.edu

Median overall survival of metastatic colorectal cancer patients treated with first- and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth factor or the epidermal growth factor receptor will further improve prospects for patients with advanced and metastatic disease. However, the optimum sequencing of chemo- and biological therapies remains to be established, as does the potential contribution of numerous agents in development.

This article has been cited by other articles:

				T. McKibbin, C. R. Frei, R. E. Greene, P. Kwan, J. Simon, and J. M. Koeller Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting Oncologist, August 1, 2008; 13(8): 876 - 885. [Abstract] [Full Text] [PDF]

				J. P. McGahan and V. P. Khatri Imaging Findings after Liver Resection by Using Radiofrequency Parenchymal Coagulation Devices: Initial Experiences Radiology, June 1, 2008; 247(3): 896 - 902. [Abstract] [Full Text] [PDF]

				R. Gao, D. K. Price, T. Sissung, E. Reed, and W. D. Figg Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1 Mol. Cancer Ther., May 1, 2008; 7(5): 1246 - 1250. [Abstract] [Full Text] [PDF]

				M. Benesch, M. Windelberg, W. Sauseng, V. Witt, G. Fleischhack, H. Lackner, H. Gadner, U. Bode, and C. Urban Compassionate use of bevacizumab (Avastin(R)) in children and young adults with refractory or recurrent solid tumors Ann. Onc., April 1, 2008; 19(4): 807 - 813. [Abstract] [Full Text] [PDF]

				P. G. Johnston The Colorectal Cancer Coalition: Reflections on the Future Oncologist, October 1, 2006; 11(9): 970 - 972. [Full Text] [PDF]